Changes

adjusting references
Line 478: Line 478:  
|<ref name=":16" />PMID: 25965575; <ref>{{Cite journal|last=Wu|first=Jing|last2=Armstrong|first2=Terri S.|last3=Gilbert|first3=Mark R.|date=2016-07|title=Biology and management of ependymomas|url=https://pubmed.ncbi.nlm.nih.gov/27022130|journal=Neuro-Oncology|volume=18|issue=7|pages=902–913|doi=10.1093/neuonc/now016|issn=1523-5866|pmc=4896548|pmid=27022130}}</ref>PMID:27022130
 
|<ref name=":16" />PMID: 25965575; <ref>{{Cite journal|last=Wu|first=Jing|last2=Armstrong|first2=Terri S.|last3=Gilbert|first3=Mark R.|date=2016-07|title=Biology and management of ependymomas|url=https://pubmed.ncbi.nlm.nih.gov/27022130|journal=Neuro-Oncology|volume=18|issue=7|pages=902–913|doi=10.1093/neuonc/now016|issn=1523-5866|pmc=4896548|pmid=27022130}}</ref>PMID:27022130
 
|}
 
|}
<references />
+
<ref>{{Cite journal|last=Neill|first=Stewart G.|last2=Hauenstein|first2=Jennifer|last3=Li|first3=Marilyn M.|last4=Liu|first4=Yajuan J.|last5=Luo|first5=Minjie|last6=Saxe|first6=Debra F.|last7=Ligon|first7=Azra H.|date=2020-05|title=Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors|url=https://pubmed.ncbi.nlm.nih.gov/32203924|journal=Cancer Genetics|volume=243|pages=19–47|doi=10.1016/j.cancergen.2020.02.004|issn=2210-7762|pmid=32203924}}</ref><references />